10 May 23
The growing burden of many CNS conditions such as Alzheimer’s or Parkinson’s disease, multiple sclerosis and chronic pain threatens to overwhelm healthcare resources. While there are many opportunities for new CNS therapeutics, the connections between target and CNS diseases are only slowly being elucidated. tranScrip’s expertise and capabilities in CNS & Pain extend across a wide range of indications such as epilepsy, neurodegenerative diseases, stroke, sleep disorders, depression, schizophrenia, ADHD and pain. We cover all phases of the product lifecycle and support and guide our clients to meet their targets even if this means challenging the current clinical and regulatory paradigms.
Click here to read the full brochure.
Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts can support you to maximise the value of your products. Whatever your project requires, we have the expertise to meet your needs.